Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort Study of the Effect of Lenvatinib Combined With TACE in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT03838796 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03838796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort Study of the Effect of Lenvatinib Combined With TACE in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Lead sponsor
Fudan University
Phase
Not applicable
Overall status
Unknown status
Start date
January 3, 2019
Completion date
June 30, 2023
Enrollment
297 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma